Profil
David Hyman has worked as a Chief Medical Officer at Eli Lilly & Co. since 2023 and at Loxo Oncology, Inc. since 2020.
Postes actifs de David Hyman
| Sociétés | Poste | Début |
|---|---|---|
| LOXO ONCOLOGY INC | Directeur Technique/Scientifique/R&D | 01/01/2020 |
| ELI LILLY AND COMPANY | Directeur Technique/Scientifique/R&D | 16/10/2023 |
Expériences
Fonctions occupées
Relations
52
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
